Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis. METHODS: In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concomitant topical agents. The primary end point was the mean percent change in the visual-analogue scale (VAS) score for pruritus (range, 0 to 100, with higher scores indicating worse pruritus) from baseline to week 16. Secondary end points included the time course of change in the VAS score for pruritus up to week 4, the change in the Eczema Area and Severity Index (EASI) score (range, 0 to 72, with higher scores indicating greater severity), a score of 4 or less on the Dermatology Life Quality Index (DLQI; range, 0 to 30, with higher scores indicating a greater effect on daily life), a score of 7 or less on the Insomnia Severity Index (ISI; range, 0 to 28, with higher scores indicating greater severity), and safety. RESULTS: A total of 143 patients were randomly assigned to receive nemolizumab and 72 to receive placebo. The median VAS score for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was -42.8% in the nemolizumab group and -21.4% in the placebo group (difference, -21.5 percentage points; 95% confidence interval, -30.2 to -12.7; P<0.001). The mean percent change in the EASI score was -45.9% with nemolizumab and -33.2% with placebo. The percentage of patients with a DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group; the percentage of patients with an ISI score of 7 or less was 55% and 21%, respectively. The incidence of injection-related reactions was 8% with nemolizumab and 3% with placebo. CONCLUSIONS: In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. The incidence of injection-site reactions was greater with nemolizumab than with placebo. Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. (Funded by Maruho; JapicCTI number, 173740.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The EASI score showed a moderate improvement of 46% with nemolizumab versus 33% in the placebo group192.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
In the citing paper
“The overall efficacy in pruritus in combination with TCSs was further confirmed in a phase III study over 16 weeks with a decrease of 43% versus 21% in the placebo group as measured by the visual analogue scale score.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011) · Sleep · doi:10.1093/sleep/34.5.601 · Cited by 4,620
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Research works printed but not linked: 1
- Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019;1:CD012167-CD012167.30666626
Cited by
Items 201–300 of 369
Miyawaki, K., Nakashima, C., & Otsuka, A. (2023) · European Journal of Dermatology · doi:10.1684/ejd.2023.4551 · Cited by 6
Pruritogens in pemphigoid diseases: Possible therapeutic targets for a burdensome symptom
Hiroyasu, S., Barit, J. J. G., Hiroyasu, A., & Tsuruta, D. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16652 · Cited by 6
Localized Delivery of Bioactives using Structured Liposomal Gels
Kumar, D., Dua, K., & Tiwari, S. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128263001231102053654 · Cited by 7
Current and Emerging Biologics for Atopic Dermatitis
Nevid, M. Z., & Boguniewicz, M. (2024) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2024.08.001 · Cited by 7
Novel therapies and the potential for a personalized approach to atopic dermatitis
Balakirski, G., & Novak, N. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000759 · Cited by 5
Katsuta, M., Kamide, R., Ishiuji, Y., Nobeyama, Y., & Asahina, A. (2024) · Acta Dermato Venereologica · doi:10.2340/actadv.v104.40634 · Cited by 5
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Dermatitis · doi:10.1177/17103568251380242 · Cited by 5
Targeting the itch–scratch vicious circle in atopic eczema
Barbarot, S. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21027 · Cited by 5
Interleukin antagonists for atopic dermatitis: a new era of therapy
Tsiogka, A., Paschou, E., Koumaki, D., Vakirlis, E., & Gregoriou, S. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2347294 · Cited by 5
In vitro models for investigating itch
Mießner, H., Seidel, J. A., & Smith, E. S. J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.984126 · Cited by 6
Nemolizumab for the treatment of atopic dermatitis
Rodrigues, E., Domingues, J., Alvarenga, J. M., Chovatiya, R., & Torres, T. R. (2025) · Journal of Dermatological Treatment · doi:10.1080/09546634.2025.2576134 · Cited by 4
Zhang, H., Xiang, W., Tong, Y., Jiang, X., & Guo, L. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09115-5 · Cited by 4
Rethinking interleukin-31: A neuroimmune orchestrator of itch beyond Th2 immunity
Irie, H., & Kabashima, K. (2026) · Allergology International · doi:10.1016/j.alit.2026.04.004 · Cited by 5
Self-citationTanaka, A., Yuasa, A., Kamei, K., Nagano, M., Murofushi, T., Bjerke, A., Nakamura, K., & Ikeda, S. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17234 · Cited by 4
A novel treatment approach for atopic dermatitis
Brunner, P. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01488-0 · Cited by 4
Revisiting immunotherapeutic strategies for the management of atopic dermatitis
Siwe, G. T., Fajemisin, E. A., Mugeri, M., Naran, K., & Barth, S. (2024) · doi:10.37349/eaa.2024.00052 · Cited by 4
Clinical factors predicting nemolizumab response in atopic dermatitis
Masuo, Y., Yonekura, S., Nakajima, S., Sawada, Y., & Kabashima, K. (2025) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2025.100457 · Cited by 4
Self-citationBioactive PLGA polymer nanoparticle loaded gels for atopic dermatitis treatment
Park, E. J., Yap, B. L. H., Wang, X., Poh, Q. Z., Tan, C. H., Koh, L. F., Common, J., & Teo, P. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-06688-w · Cited by 4
Katsuta, M., Osawa, A., Ishiuji, Y., Fujii, S., Kanbe, M., Asahina, A., & Nobeyama, Y. (2025) · JAAD Case Reports · doi:10.1016/j.jdcr.2025.03.026 · Cited by 4
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.44310 · Cited by 4
Anti‐pruritic effect of isothiocyanates: Potential involvement of toll‐like receptor 3 signaling
Moriyama, M., Konno, M., Serizawa, K., Yuzawa, N., Majima, Y., Hayashi, I., Suzuki, T., & Kainoh, M. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1038 · Cited by 5
Merkel, T., Navarini, A. A., & Mueller, S. M. (2024) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12948 · Cited by 4
Sato, E., Arima, H., Ito, K., Iwata, M., & Imafuku, S. (2024) · Journal of Cutaneous Immunology and Allergy · doi:10.3389/jcia.2024.12974 · Cited by 4
Igarashi, A., Yoshida, T., Sunaga, Y., Nawata, H., & Arima, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061872 · Cited by 4
Ogura, M., Endo, K., Suzuki, T., & Homma, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246630 · Cited by 4
Phototherapy for Prurigo Nodularis: Our Experience and a Review of the Literature
Arrieta, A., Jaka, A., del Alcázar, E., Blanco, M., & Carrascosa, J. M. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2020.11.006 · Cited by 4
Biological Therapies for Pediatric Atopic Dermatitis - A Review
Milano, G., Forestieri, S., Tedeschi, M., Licari, A., Brazzelli, V., & Marseglia, G. L. (2023) · Current Pediatric Reviews · doi:10.2174/1573396320666230912103136 · Cited by 4
Suehiro, M., & Tanaka, A. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.17023 · Cited by 3
Sato, E., Obonai, N., Iwata, M., Ito, K., & Imafuku, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639932 · Cited by 4
Basophils in atopic dermatitis
Das, M., & Geha, R. S. (2025) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2025.11.005 · Cited by 4
Liu, W., Zhang, H., Chen, X., Xiao, Y., & Su, J. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09127-1 · Cited by 3
Bang, Y. J., Lee, B. H., Jeong, S., Moon, Y., Lee, J. H., Kim‐Schulze, S., Lee, J. S., Ahn, J., Ju, H. J., Bae, J. M., et al. (2026) · Allergology International · doi:10.1016/j.alit.2026.02.004 · Cited by 3
Serra‐Baldrich, E., Santamaria‐Babí, L. F., & Silvestre, J. F. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.06.001 · Cited by 3
Forecasting of Atopic Dermatitis in Newborns
Hajiyeva, N., Gafarov, I., Hajiyeva, A., Sultanova, N., & Panahova, T. T. P. (2022) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_933_21 · Cited by 3
Brooks, S. G., Lopez, L. M., Mashoudy, K. D., Yosipovitch, G., & Czarnowicki, T. (2024) · Dermatitis · doi:10.1089/derm.2024.0261 · Cited by 4
The evolving therapeutic landscape in atopic dermatitis
Hernandez-Zarate, L., Gómez-Núñez, C. A., Narváez-Labuhn, S., Morales-Velázquez, G., & González-Uribe, V. (2025) · doi:10.37349/eaa.2025.100966 · Cited by 4
Biologics in atopic dermatitis
Chan, S. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000740 · Cited by 3
Kamei, K., Saeki, H., Tsuchiya, T., Hirose, T., Campos‐Alberto, E., Matsumoto, F., Yoshii, N., & Imafuku, S. (2021) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12180 · Cited by 3
Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis
Freemantle, N., & Piketty, C. (2021) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0727 · Cited by 3
New therapies in atopic dermatitis
Steuer-Hajdú, K., & Szegedi, A. (2021) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2021.97.5.1 · Cited by 5
Atopisches Ekzem: Störfeuer für eine Dreiecksbeziehung
Lauffer, F., & Biedermann, T. (2021) · Deutsches Ärzteblatt · doi:10.3238/persderma.2021.06.18.04 · Cited by 3
Kaneda, N. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22150 · Cited by 3
Real-world clinical efficacy of nemolizumab in Japanese patients with atopic dermatitis
Watanabe, Y., Ishiuji, Y., Ogawa‐Tominaga, M., Katsuta, M., & Asahina, A. (2023) · Itch · doi:10.1097/itx.0000000000000071 · Cited by 3
Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials
Obed, O., Chong, A. C., Su, M., & Ong, P. Y. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2345643 · Cited by 4
Immediate and sustained efficacy of nemolizumab in chronic pruritus of unknown origin
Nakayama, S., Yonekura, S., Nakajima, S., & Kabashima, K. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17679 · Cited by 2
Self-citationNew and Emerging Pharmacotherapies for Pruritus: A Systematic Review and Network Meta-Analysis
Li, H., Arthur, A., Forouzandeh, M., Pomputius, A. F., Cuervo‐Pardo, L., & Montanez-Wiscovich, M. E. (2025) · Dermatitis · doi:10.1089/derm.2023.0419 · Cited by 3
Methods to Validate Digital Health Technologies for Dermatology
Park, J. J.-Y., Richards, D., Tseng, P.-H., Ebata, T., Ikoma, A., Vakharia, P. P., Rangel, S. M., Paller, A. S., & Xu, S. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.08.013 · Cited by 2
Vieira, A. C. P., Akabane, M. A. C. C., Caletti, G. C. G., Heffel, K. K., & Silva, A. T. O. E. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2025.501210 · Cited by 2
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Cureus · doi:10.7759/cureus.96605 · Cited by 2
Therapeutic advances in pruritus as a model of personalized medicine
Auyeung, K. L., Kubofcik, R., & Kim, B. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70169 · Cited by 3
Boesjes, C. M., van der Gang, L. F., Achten, R., Bakker, D. S., van der Rijst, L. P., Dekkers, C., van Wijk, F., Haeck, I. M., de Bruin-Weller, M. S., & de Graaf, M. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2597850 · Cited by 7
Seok, J., Kim, S.-Y., Lee, W. G., Shin, M. K., Lee, D. H., Seo, Y., Cho, S., Park, K. Y., Son, S. W., Lee, S., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04763-y · Cited by 3
Pink, A. E., Houghton, J. B., White, H., Schiavo, S., Piketty, C., Ulianov, L., Rout, R., Jack, K., Subramanian, R., & Puelles, J. (2026) · Dermatology and Therapy · doi:10.1007/s13555-025-01647-0 · Cited by 2
Understanding cutaneous sensory syndromes: diagnostic challenges and treatment implications
Patel, J. D., & Jafferany, M. (2026) · Clinical and Experimental Dermatology · doi:10.1093/ced/llag107 · Cited by 2
Design of intradermally permeable liposomes: Focus on surface properties and lipid composition
Ibaraki, H., Oogi, C., Oashi, K., Hirochi, Y., Kanazawa, T., & Takashima, Y. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108347 · Cited by 2
Bonnekoh, H., Butze, M., & Metz, M. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14678_g · Cited by 3
Dupilumab Failure in Treating Dermatomyositis-Associated Pruritus
O’Brien, M. A., Hsu, S., Shevchenko, A., & Quartey, A. (2022) · Cureus · doi:10.7759/cureus.28270 · Cited by 2
Kishimoto, M., Deshpande, G. A., Fukui, S., Komagata, Y., Ohyama, M., & Kaname, S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2149494 · Cited by 2
[Translated article] Pruritus in Dermatology: Part 2—Diseases and Their Treatment
Navarro‐Triviño, F. J. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.007 · Cited by 4
Latest Breakthroughs in the Treatment of Atopic Dermatitis
Skayem, C., & Duong, T. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.104344 · Cited by 2
Can Serum Biomarkers for Prurigo Nodularis Expose Pathophysiology or Just Treatment Response?
Kashem, S. W., & Fassett, M. S. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2608 · Cited by 2
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
Ma, E. Z., Gage, D., Imo, B. U., Oladipo, O. O., Akiska, Y. M., Shahsavari, S., Lee, K. K., Kollhoff, A. L., Manjunath, J., Pritchard, T., et al. (2024) · Archives of Dermatological Research · doi:10.1007/s00403-024-03511-1 · Cited by 2
Katagiri, R., Matsuo, S., Ikegami, H., Kaneko, A., Arima, A., Chiba, S., & Sasaki, M. (2025) · Birth Defects Research · doi:10.1002/bdr2.2442 · Cited by 2
Horimukai, K., Kinoshita, M., & Takahata, N. (2025) · Cureus · doi:10.7759/cureus.78214 · Cited by 2
Cost–utility analysis of upadacitinib vs. dupilumab for atopic dermatitis in Australia
Li, G. X., Sun, H. Y., Pham, J. P., Tatian, A., Polcz, M., Chee, S., Shih, S. T. F., & Sebaratnam, D. F. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf097 · Cited by 2
Nemolizumab-induced psoriasiform dermatitis
Absil, G., Collins, P., Colleye, O., Dezfoulian, B., & Nikkels, A. (2025) · JAAD Case Reports · doi:10.1016/j.jdcr.2025.05.057 · Cited by 2
Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy
Kumar, P., Ashawat, M. S., Kumar, A., Guleria, A. S., & Thakur, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010311098240530104530 · Cited by 2
Yoshino, T., Horiba, Y., Mimura, M., & Watanabe, K. (2022) · Complementary Medicine Research · doi:10.1159/000524778 · Cited by 1
Nemolizumab as a Novel Therapeutic Option for Refractory Prurigo Chronica Multiformis: A Case Report
Nakayama, S., Yonekura, S., Nakajima, S., & Kabashima, K. (2025) · International Journal of Dermatology · doi:10.1111/ijd.17821 · Cited by 1
Self-citationDarchini‐Maragheh, E., & Moussa, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01160-6 · Cited by 1
Tanaka, R., Tanaka, S., & Fujii, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04306-5 · Cited by 2
Wang, J., Yuan, B., Zhong, S., Liu, H., Zhang, J., Chen, X., Chen, Y., & Liu, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202403020r · Cited by 1
Guideline-based Approach in the Management of Atopic Dermatitis
Bingemann, T., Weis, E. L., El-Feghaly, J. R., & Benedetto, A. D. (2025) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2025.06.010 · Cited by 1
Structural insights into IL-31 signaling inhibition by a neutralizing antibody
Guo, T., Zheng, Y., Fan, Z., Liu, P., Chai, Y., Liao, X., Zhang, C., Pang, X., Li, D., Gao, F., et al. (2025) · Structure · doi:10.1016/j.str.2025.09.002 · Cited by 1
The role of type 2 inflammation in the pathogenesis of atopic dermatitis
Elisyutina, O. G., Smolnikov, E. V., Chernushevich, D. D., Litovkina, A. O., Byazrova, M. G., Левкова, Е. А., & Fedenko, E. S. (2025) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2025-29-3-365-384 · Cited by 1
Yao, S., Zhao, Y., Li, Z., Lou, H., & Zhang, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s551942 · Cited by 1
Efficacy and safety of nemolizumab in paediatric atopic dermatitis: A 24‐week real‐world case series
Takahashi, Y., Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70218 · Cited by 1
Cai, W., Fu, L., Wu, Y., Yao, Y., & Zhang, J. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70268 · Cited by 1
Sugiyama, A., Nakahara, T., Kojima, K., Nishie, H., Nishimura, M., & Hiramoto, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248657 · Cited by 1
Lao, Y.-D., Zhang, H., Cai, Y., Chen, M., Wu, L., He, X., & Deng, W.-Y. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1680658 · Cited by 1
Combination therapy with dupilumab and nemolizumab for refractory itch in atopic dermatitis
Nguyen, W., Bahar, K., & Yamauchi, P. S. (2026) · JAAD Case Reports · doi:10.1016/j.jdcr.2026.01.010 · Cited by 1
24-week real world outcomes of nemolizumab in patients with prurigo nodularis
Mima, Y., Yamamoto, M., & Iozumi, K. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2624225 · Cited by 1
Xiong, M., Gao, Q., & Duan, X. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2650070 · Cited by 1
Jin, C., DING, Z., Chien, P. N., & Heo, C. Y. (2026) · Allergies · doi:10.3390/allergies6020016 · Cited by 1
Banović, F., Austel, M. G., Johnson, L., & von Simson, C. (2026) · Veterinary Dermatology · doi:10.1111/vde.70102 · Cited by 1
Li, L., Yu, J., Huang, D., Zhou, H., Mo, N., Hu, W., & Qian, F. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04692-7 · Cited by 1
Clinical and Psychological Impact of Pruritus Related to Skin Barrier Damage
la Cruz, H. V., & Magid, M. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01072-9 · Cited by 1
Advances in Therapy for Atopic Dermatitis
Zhou, N. Y., Bilimoria, S. N., & Lio, P. (2022) · Journal of the Dermatology Nurses’ Association · doi:10.1097/jdn.0000000000000658 · Cited by 1
Perkembangan Terapi Sistemik pada Pruritus
Andardewi, M. F., Budianti, W. K., Legiawati, L., & Irawan, Y. (2022) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v28i1.2203 · Cited by 4
Atopic Dermatitis and Allergic Contact Dermatitis
Boguniewicz, M., Fonacier, L. S., & Leung, D. Y. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-80912-2.00011-1 · Cited by 1
Atopik Dermatit Güncel Patofizyolojisi
Çalıcıoğlu, F., Avcı, A., Ertaş, R., & Ulaş, Y. (2024) · Journal of Anatolian Medical Research · doi:10.55694/jamer.1403931 · Cited by 1
Sung, M., Koh, Y., Kim, M., Kim, H., Na, J., Nahm, D., Min, T. K., Park, Y., Lee, D. H., Lee, M.-H., et al. (2024) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2024.12.2.58 · Cited by 1
Investigation of the effect of nemolizumab on pruritus in patients with atopic dermatitis
Mikami, M. (2024) · 日本臨床皮膚科医会雑誌 · doi:10.3812/jocd.41.594 · Cited by 1
Promising Strategies for the Management of Burn-Wound-Associated Pruritus
Tenenhaus, M., & Rennekampff, H. (2025) · European Burn Journal · doi:10.3390/ebj6010002 · Cited by 1
Nemolizumab to target the itch–scratch cycle in paediatric atopic dermatitis
Lloyd-Lavery, A. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad319 · Cited by 1
Pruritus, Prurigo and Lichen Simplex
Ständer, S., & Yosipovitch, G. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook081 · Cited by 2
Quoi de neuf en thérapeutique dermatologique ?
Sbidian, É. (2020) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(20)31107-8
Biologicals in Atopic Dermatitis
Samudrala, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95229
Future perspective of the treatment for pediatric atopic dermatitis
Katoh, N. (2021) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.35.233
Metadata
- Authors
- Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M.
- Affiliations
- Kyoto University (JP)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-07-09
- Volume
- 383
- Issue
- 2
- Pages
- 141-150
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3040869725
- Cited by
- 361
- References
- 39
- Citations by year
- 2026: 37 · 2025: 68 · 2024: 57 · 2023: 67 · 2022: 51 · 2021: 73 · 2020: 7
- FWCI
- 36.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Maruho co., Ltd.
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, pruritus, nemolizumab, monoclonal antibodies, topical corticosteroids, topical calcineurin inhibitors, Eczema Area and Severity Index, Dermatology Life Quality Index, insomnia, Japanese patients, treatment efficacy and safety, visual analogue scale
- MeSH terms
- Administration, Topical, Adolescent, Adult, Aged, Aged, 80 and over, Dermatitis, Atopic, Double-Blind Method, Drug Therapy, Combination, Female, Glucocorticoids, Histamine Antagonists, Humans, Injections, Subcutaneous, Male, Middle Aged, Pruritus, Young Adult, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Visual Analog Scale, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.